Evidence map›Paper›PMID 28732024›Full record

ArticlePloS one2017

4-(Nitrophenylsulfonyl)piperazines mitigate radiation damage to multiple tissues.

Ewa D Micewicz, Kwanghee Kim, Keisuke S Iwamoto, Josephine A Ratikan, Genhong Cheng, Gayle M Boxx, Robert D Damoiseaux, Julian P Whitelegge, Piotr Ruchala, Christine Nguyen and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Radiation-induced tissue damage and response.The Journal of pathology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Ewa D MicewiczDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
Kwanghee KimDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
Keisuke S IwamotoDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
Josephine A RatikanDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
Genhong ChengDepartment of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, United States of America.
Gayle M BoxxDepartment of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, United States of America.
Robert D DamoiseauxMolecular Screening Shared Resource, University of California at Los Angeles, Los Angeles, California, United States of America.
Julian P WhiteleggePasarow Mass Spectrometry Laboratory, University of California at Los Angeles, Los Angeles, California, United States of America.
Piotr RuchalaPasarow Mass Spectrometry Laboratory, University of California at Los Angeles, Los Angeles, California, United States of America.
Christine NguyenDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
Prabhat PurbeyDepartment of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, United States of America.
Joseph LooDepartment of Chemistry and Biochemistry, University of California at Los Angeles, Los Angeles, California, United States of America.
Gang DengDepartment of Chemistry and Biochemistry, University of California at Los Angeles, Los Angeles, California, United States of America.
Michael E JungDepartment of Chemistry and Biochemistry, University of California at Los Angeles, Los Angeles, California, United States of America.
James W SayreSchool of Public Health, Biostatistics and Radiology, University of California at Los Angeles, Los Angeles, California, United States of America.
Andrew J NorrisBCN Biosciences, LLC, Pasadena, California, United States of America.
Dörthe SchaueDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.ORCID http://orcid.org/0000-0002-5674-678X
William H McBrideDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, California, United States of America.
University of California, Los Angeles · USBCN Biosciences (United States) · US

Funding

UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
NIAID NIH HHS U19 AI067769
6 · The paper itself

Abstract

Our ability to use ionizing radiation as an energy source, as a therapeutic agent, and, unfortunately, as a weapon, has evolved tremendously over the past 120 years, yet our tool box to handle the consequences of accidental and unwanted radiation exposure remains very limited. We have identified a novel group of small molecule compounds with a 4-nitrophenylsulfonamide (NPS) backbone in common that dramatically decrease mortality from the hematopoietic acute radiation syndrome (hARS). The group emerged from an in vitro high throughput screen (HTS) for inhibitors of radiation-induced apoptosis. The lead compound also mitigates against death after local abdominal irradiation and after local thoracic irradiation (LTI) in models of subacute radiation pneumonitis and late radiation fibrosis. Mitigation of hARS is through activation of radiation-induced CD11b+Ly6G+Ly6C+ immature myeloid cells. This is consistent with the notion that myeloerythroid-restricted progenitors protect against WBI-induced lethality and extends the possible involvement of the myeloid lineage in radiation effects. The lead compound was active if given to mice before or after WBI and had some anti-tumor action, suggesting that these compounds may find broader applications to cancer radiation therapy.

Indexed as

Acute Radiation SyndromeAnimalsAntineoplastic AgentsApoptosisCells, CulturedFemaleMaleMiceMice, Inbred C3HMice, Inbred C57BLMyeloid CellsPiperazinesAntineoplastic AgentsPiperazines

Identifiers

PMID28732024
PMCPMC5521796
OpenAlexW2739367335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.